Shanghai, China

Zhenxing Du


 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zhenxing Du: Innovator in Pharmaceutical Chemistry

Introduction

Zhenxing Du is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on quinazolin-4-one derivatives. His research focuses on developing compounds that can aid in the treatment of diseases mediated by class I PI3K kinases.

Latest Patents

Zhenxing Du holds 1 patent for his invention titled "Substituted quinazolin-4-one derivatives." This patent provides a detailed description of substituted quinazolin-4-one compounds, including their formula and the various pharmaceutically acceptable salts and solvates. The compounds are designed to target disorders or diseases influenced by the activity of class I PI3K kinases, showcasing their potential therapeutic applications.

Career Highlights

Zhenxing Du is currently employed at Novartis AG, a leading global healthcare company. His role at Novartis allows him to collaborate with other experts in the field and contribute to groundbreaking research in pharmaceuticals. His work is characterized by a commitment to innovation and the development of effective treatments.

Collaborations

Zhenxing Du has worked alongside notable colleagues such as Samuel Hintermann and Konstanze Hurth. These collaborations have further enriched his research and have led to advancements in the understanding of pharmaceutical compounds.

Conclusion

Zhenxing Du's contributions to pharmaceutical chemistry, particularly through his patented work on quinazolin-4-one derivatives, highlight his role as an innovator in the field. His ongoing research at Novartis AG continues to pave the way for new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…